CN111788182B - 毒蕈碱性乙酰胆碱受体m4的拮抗剂 - Google Patents

毒蕈碱性乙酰胆碱受体m4的拮抗剂 Download PDF

Info

Publication number
CN111788182B
CN111788182B CN201980012827.5A CN201980012827A CN111788182B CN 111788182 B CN111788182 B CN 111788182B CN 201980012827 A CN201980012827 A CN 201980012827A CN 111788182 B CN111788182 B CN 111788182B
Authority
CN
China
Prior art keywords
azabicyclo
pyridazin
amine
hexane
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980012827.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111788182A (zh
Inventor
C·W·林斯利
P·J·康恩
D·W·恩格斯
J·L·恩吉尔斯
A·M·本德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN111788182A publication Critical patent/CN111788182A/zh
Application granted granted Critical
Publication of CN111788182B publication Critical patent/CN111788182B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980012827.5A 2018-02-02 2019-02-01 毒蕈碱性乙酰胆碱受体m4的拮抗剂 Expired - Fee Related CN111788182B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625656P 2018-02-02 2018-02-02
US62/625,656 2018-02-02
PCT/US2019/016300 WO2019152809A1 (en) 2018-02-02 2019-02-01 Antagonists of the muscarinic acetylcholine receptor m4

Publications (2)

Publication Number Publication Date
CN111788182A CN111788182A (zh) 2020-10-16
CN111788182B true CN111788182B (zh) 2023-09-26

Family

ID=67480022

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012827.5A Expired - Fee Related CN111788182B (zh) 2018-02-02 2019-02-01 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Country Status (10)

Country Link
US (1) US11414406B2 (https=)
EP (1) EP3746421B1 (https=)
JP (1) JP7352294B2 (https=)
KR (1) KR20200116945A (https=)
CN (1) CN111788182B (https=)
AU (1) AU2019216492A1 (https=)
CA (1) CA3090130A1 (https=)
IL (1) IL276411B2 (https=)
WO (1) WO2019152809A1 (https=)
ZA (1) ZA202004638B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12606549B2 (en) 2020-11-26 2026-04-21 Rezubio Pharmaceuticals Co., Ltd Anticholinergic agents

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12600726B2 (en) 2017-07-12 2026-04-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
AU2020358000A1 (en) * 2019-10-04 2022-04-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056811A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2006035282A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101268071A (zh) * 2005-10-21 2008-09-17 诺瓦提斯公司 治疗精神病和神经退行性疾病的新1-氮杂-双环烷基衍生物
CN106459039A (zh) * 2014-05-23 2017-02-22 豪夫迈·罗氏有限公司 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US20040044029A1 (en) 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
EP2129660A2 (en) * 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN101230058A (zh) 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN103102352B (zh) 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3371164B1 (en) 2015-11-06 2022-03-16 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
KR20180110132A (ko) 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
AU2018313802A1 (en) * 2017-08-08 2020-02-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019079410A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
AU2018360581A1 (en) 2017-10-31 2020-06-11 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056811A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2006035282A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101268071A (zh) * 2005-10-21 2008-09-17 诺瓦提斯公司 治疗精神病和神经退行性疾病的新1-氮杂-双环烷基衍生物
CN106459039A (zh) * 2014-05-23 2017-02-22 豪夫迈·罗氏有限公司 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN：2164592-45-2，2152087-70-0，2148484-96-0，2029853-92-5，2028000-90-8，2025026-23-5，2024724-04-5，2001685-84-1，1995218-19-3;美国化学会;《STNEXT》;第1-5页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12606549B2 (en) 2020-11-26 2026-04-21 Rezubio Pharmaceuticals Co., Ltd Anticholinergic agents

Also Published As

Publication number Publication date
CA3090130A1 (en) 2019-08-08
EP3746421B1 (en) 2023-11-29
IL276411B1 (en) 2023-12-01
WO2019152809A1 (en) 2019-08-08
US11414406B2 (en) 2022-08-16
CN111788182A (zh) 2020-10-16
EP3746421A1 (en) 2020-12-09
ZA202004638B (en) 2023-02-22
EP3746421A4 (en) 2021-10-27
IL276411B2 (en) 2024-04-01
US20200369650A1 (en) 2020-11-26
JP7352294B2 (ja) 2023-09-28
AU2019216492A1 (en) 2020-08-20
IL276411A (en) 2020-09-30
JP2021513519A (ja) 2021-05-27
KR20200116945A (ko) 2020-10-13

Similar Documents

Publication Publication Date Title
CN111788182B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN111491920B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11325896B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US11352344B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN110891569A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US20230122344A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP7099725B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US20240010640A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US12516067B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
CN111406058A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230926

CF01 Termination of patent right due to non-payment of annual fee